Teva Pharma (TEVA) PT Lowered to $14 at Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Teva Pharma (TEVA) Gains as Billionaire Blavatnik Considers Buying Large Stake
November 6, 2017 6:41 AM ESTBeaten-down Israeli pharmaceutical stock Teva Pharma (NYSE: TEVA) is gaining 2% in pre-open trade Monday following reports over the weekend from Globes that billionaire Len Blavatnik is considering taking a large stake in the company. The report said Blavatnik may be contemplating buying Allergan's (NYSE: AGN) 10% stake.
... MoreTeva Pharma (TEVA) PT Lowered to $13 at Goldman Sachs
November 6, 2017 5:28 AM ESTGoldman Sachs lowered its price target on Teva Pharma (NYSE: TEVA) to $13.00 (from $18.00) while maintaining a Neutral rating.
Analyst Jami Rubin says significant cost restructuring is required for Teva to stabilize. The analyst expects the equity to remain under pressure until the... More
Top five unique options volume: FB SBUX FL GE TEVA
November 3, 2017 9:56 AM EDTTop five unique options volume: FB SBUX FL GE TEVA
... MoreDeutsche Bank Downgrades Teva Pharma (TEVA) to Hold
November 3, 2017 5:54 AM EDTDeutsche Bank downgraded Teva Pharma (NYSE: TEVA) from Buy to Hold with a price target of $14.00 (from $22.00).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $11.23 yesterday.
... MoreTeva Pharma (TEVA) PT Slashed to $10 at Cantor Fitzgerald
November 2, 2017 1:39 PM EDTCantor Fitzgerald analyst Louise Chen lowered her price target on Teva Pharma (NYSE: TEVA) to $10.00 (from $17.00) while maintaining a Neutral rating following Q3 miss and lower guide.
Chen thinks the company has some meaningful headwinds which need to be addressed before the... More
Teva Pharma (TEVA) Plunges to Fresh Low, Down 16%
November 2, 2017 9:33 AM EDTTeva Pharma (NYSE: TEVA) Plunges to Fresh Low, Down 16%
... MoreUPDATE: Teva Pharma (TEVA) Misses Q3 EPS by 4c, Q4 Guidance Comes in Light
November 2, 2017 7:00 AM EDT(Updated - November 2, 2017 7:05 AM EDT)
Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.00, $0.04 worse than the analyst estimate of $1.04. Revenue for the quarter came in at $5.61 billion versus the consensus estimate of $5.62... More
